Target Name: CD200R1L
NCBI ID: G344807
Other Name(s): Cell surface glycoprotein CD200 receptor 2 (isoform 1) | HuCD200R2 | CD200R2 | cell surface glycoprotein CD200 receptor 1-like | CD200 cell surface glycoprotein receptor 2 | Cell surface glycoprotein CD200 receptor 2 | Cell surface glycoprotein CD200 receptor 1-like | cell surface glycoprotein OX2 receptor 2 | MO2R2_HUMAN | CD200 receptor-like 2 | CD200R1L variant 1 | CD200 receptor 1 like, transcript variant 1 | CD200 receptor 2 | CD200 cell surface glycoprotein receptor-like 2 | CD200 receptor 1 like | huCD200R2 | Cell surface glycoprotein OX2 receptor 2 | CD200 cell surface glycoprotein receptor-like a | Cell surface glycoprotein CD200 receptor 02 | CD200RLa

CD200R1L: A Promising Drug Target and Biomarker for Multiple Sclerosis

Multiple sclerosis (MS) is a chronic autoimmune disease characterized by the destruction of the central nervous system (CNS). The immune system attacks the myelin sheath surrounding nerve fibers, leading to muscle, joint, and vision problems. There are currently no approved disease-modifying therapies for MS, and existing treatments are only designed to manage symptoms. Therefore, there is a strong need for new treatments that can slow the progression of MS and potentially improve outcomes.

CD200R1L: A Potential Drug Target and Biomarker

The cell surface glycoprotein CD200 receptor 2 (isoform 1) is a protein that is expressed in various tissues and cells, including the CNS. It is involved in the immune response and has been implicated in the development and progression of MS. Several studies have suggested that CD200R1L may be a drug target or biomarker for MS. In this article, we will explore the potential of CD200R1L as a drug target and biomarker for MS.

CD200R1L as a Drug Target

CD200R1L is a protein that is expressed in the CNS and is involved in the immune response. It has been shown to play a role in the regulation of immune cell function and has been implicated in the development and progression of MS. Several studies have suggested that CD200R1L may be a potential drug target for MS.

One of the potential mechanisms by which CD200R1L may contribute to the development of MS is by regulating the activity of immune cells. There is evidence to suggest that CD200R1L plays a role in the regulation of T-cell function, and that it may be involved in the development of tolerance to CD200R1L. Several studies have shown that individuals with MS have lower levels of CD200R1L than healthy individuals, and that these levels are associated with increased immune activity in the CNS.

Another potential mechanism by which CD200R1L may contribute to the development of MS is by contributing to the destruction of the myelin sheath. There is evidence to suggest that CD200R1L is involved in the destruction of myelin sheath in the CNS, and that this may contribute to the development of MS. Several studies have shown that individuals with MS have increased levels of CD200R1L in their brains and that these levels are associated with the destruction of myelin sheath.

In addition to these potential mechanisms, there is also evidence to suggest that CD200R1L may be involved in the regulation of the immune response and that this may contribute to the development of MS. Several studies have shown that CD200R1L is involved in the regulation of immune cell function, and that this may be involved in the development of MS.

CD200R1L as a Biomarker

CD200R1L has also been suggested as a potential biomarker for MS. Several studies have shown that individuals with MS have lower levels of CD200R1L than healthy individuals, and that these levels are associated with increased immune activity in the CNS. This suggests that CD200R1L may be a useful biomarker for MS.

In addition to its potential as a drug target, CD200R1L has also been suggested as a potential biomarker for MS. Several studies have shown that individuals with MS have lower levels of CD200R1L than healthy individuals, and that these levels are associated with increased immune activity in the CNS. This suggests that CD200R1L may be a useful biomarker

Protein Name: CD200 Receptor 1 Like

Functions: May be a receptor for the CD200/OX2 cell surface glycoprotein

More Common Targets

CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1